Clinical Trial Goal
To find out if the combination of azacitidine and venetoclax is safe and works well to treat AML before allogeneic BMT
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML and are planning to receive allogeneic BMT
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Azacitidine is a drug that blocks the growth of cancer cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Azacitidine – Given as intravenous (IV) infusions or as a shot under your skin 1 time each day for 1 week
- Venetoclax – A pill that you take by mouth 1 time each day
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat AML before allogeneic BMT is new and unproven.
Locations
Sponsors
lead: Memorial Sloan Kettering Cancer Center
